key: cord-0803760-20wiriw3 authors: Behl, Tapan; Kaur, Ishnoor; Aleya, Lotfi; Sehgal, Aayush; Singh, Sukhbir; Sharma, Neelam; Bhatia, Saurabh; Al-Harrasi, Ahmed; Bungau, Simona title: CD147-spike protein interaction in COVID-19: Get the ball rolling with a novel receptor and therapeutic target date: 2021-12-01 journal: Sci Total Environ DOI: 10.1016/j.scitotenv.2021.152072 sha: adb85224186be8527c411ecd14afdaf142b8db2b doc_id: 803760 cord_uid: 20wiriw3 The combat against the Corona virus disease of 2019 (COVID-19), has created a chaos among the healthcare institutions and researchers, in turn accelerating the dire need to curtail the infection spread. The already established entry mechanism, via ACE2 has not yet successfully aided in the development of a suitable and reliable therapy. Taking in account the constant progression and deterioration of the cases worldwide, a different perspective and mechanistic approach is required, which has thrown light onto the cluster of differentiation 147 (CD147) transmembrane protein, as a novel route for SARS-CoV-2 entry. Despite lesser affinity towards COVID-19 virus, as compared to ACE2, this receptor provides a suitable justification behind elevated blood glucose levels in infected patients, retarded COVID-19 risk in women, enhanced susceptibility in geriatrics, greater infection susceptibility of T cells, infection prevalence in non-susceptible human cardiac pericytes and so on. The manuscript invokes the title role and distribution of CD147 in COVID-19 as an entry receptor and mediator of endocytosis-promoted entry of the virus, along with the “catch and clump” hypothesis, thereby presenting its Fundamental significance as a therapeutic target for potential candidates, such as Azithromycin, melatonin, statins, beta adrenergic blockers, ivermectin, Meplazumab etc. Thus, the authors provide a comprehensive review of a different perspective in COVID-19 infection, aiming to aid the researchers and virologists in considering all aspects of viral entry, in order to develop a sustainable and potential cure for the 2019 COVID-19 disease. Cyclophilin A and B bind to and activate CD147, thereby aiding in the process of interaction between viral S protein and CD147. SARS-CoV-2 enters the host cell through CD147 mediated endocytosis. Dipeptidyl peptidase 4 (DPP4) and ACE2 are the key receptors for MERS and SARS-CoV-1 respectively (Wang et al., 2013) . The life cycle of novel corona virus begins with ACE-2 receptor binding of S-protein of the viral genome leading to S-protein conformational alteration mediated fusion of envelope of the viral entity with the host cell membrane via endosomal pathway (Adnan Shereen et al., 2020) . This fusion is followed by release of the viral generic material (RNA) in the host cell, which undergoes translation and produces viral replicase polyproteins ppa1 and 1ab (Adnan Shereen et al., 2020) . The polyproteins are then cleaved to form proteinases. Irregular transcription and translation events lead to the formation of sub-genomic messenger RNA (mRNAs) from polymerase enzyme, followed by viral proteins production (Adnan Shereen et al., 2020) . These proteins and RNA genome are accumulated into virions in endoplasmic reticulum and golgi apparatus, followed by transportation and release as vesicles (Adnan Shereen et al., 2020) . The protein encoding genes include spike (S), envelope (E), membrane (M) and nucleocapsid (N) genes (Adnan Shereen et al., 2020) . Pp1ab protein and 15 nsps are encoded by the largest gene in COVID -19, i.e. orf1ab (Adnan Shereen et al., 2020) . The orf1a gene encodes for 10 nsps containing pp1ab protein . Significant alterations are observed in SARS-CoV-2 genome, like amino acid fluctuation in 8b and 3c protein as well as absence of 8a protein (Wu confirmed by a fluorescent study (Gralinski andMenachery, 2020) . The SARS-CoV-2 is considered to exhibit a single N501T mutation, that might be responsible for its enhanced affinity towards ACE2 receptors . Therefore, this data accounts for the fact that ACE-2 is an important receptor, which promotes viral entry into the host organism. Belonging to the immunoglobulin superfamily, CD147 (a highly glycosylated transmembrane protein) functions as a significant upstream regulator of matrix metalloproteinases (MMPs), which may be elevate in its concentration level, in case of diabetic and asthmatic complications . The concentration of MMPs and CD147 is mostly elevated during inflammation and tumours (Kong et al., 2014) . A study investigated the distribution of CD147 along with its transmembrane components and extracellular agonists in adaptive and innate immune cells in the periphery and the lungs, which facilitates their further study in the spread and infection by the virus . Also, CD147 is expressed in high amounts in the epithelial tissues. , 2020) . CD147 is found be greatly expressed in the bronchial biopsy and human bronchial epithelial cells (HBECs) of chronic obstructive pulmonary disease (COPD) individuals, and blood of patients with obesity, which is one of the significant comorbidities associated with COVID-19 infection (Goyal et al., 2020) . In addition to this, the extracellular ligands and transmembrane components of CD147 have been found to aid in other viral infections (Pushkarsky et al., 2001) . Viruses combine cyclophilin A and B in their virions, followed by binding via CD147 or activation of CD147-mediated signalling (Chen et al., 2005; J o u r n a l P r e -p r o o f cytokines, like interferon-gamma (INF-γ), interleukin-6 (IL-6), monocyte-chemoattractant protein (MCP-1) and tumour necrosis factor-α (TNF-α) (Zhai et al., 2016) . Recently, certain investigations have reported the role of SARS-CoV-2 infection in elevating the cytokine expression, creating cytokine storm (hypercytokinemia), which intensifies the disease condition (Saghazadeh and Rezaei, 2020; Liu et al., 2020) . This condition of hypercytokinemia is uncontrolled release of cytokines, which is observed in cases of infectious and non-infectious disorders, facilitating a hyper-inflammatory state in the host organism (Mahmudpour et al., 2020) . Azithromycin also functioned as the blocker of this RBC invasion (Zenonos et al., 2015; Wilson et al., 2015; (Muralidharan V, Striepen, 2015) , by hindering the significant initial step of formation of tight junctions, as evidently portrayed by invasion inhibition assays and experiments of live video microscopy (Wilson et al., 2015) . However, azithromycin loose the property of inhibition of viral invasion, upon removing the two significant glycan groups (Wilson et al., 2015) . Moreover, there are other possible mechanisms, such as the interference of azithromycin in ligand/receptor (PfRH5/CD147) interaction should be considered Unlike ACE2, which exhibits its role as a receptor for both binding and permeation of the SARS-CoV-2 virus into the host cell Bourgonje et al., 2020) , CD147 receptor might permit the virus to exhibit destruction in the host cell, by binding alone . Along with ACE2, CD147 has also been identified as the binding site for the viral spike protein . Angiotensin 2 and cyclophilins are reported to be significant proteins, which elevate the expression and function of CD147, in case of SARS-CoV-2 infection. Interestingly, these proteins are involved in the endothelial dysfunction, associated with heart problem, hypertension and diabetes (Zhang et al., 2017) . Cyclophilin A and B bind to and activate CD147, thereby aiding in the process of interaction between viral S protein and CD147 . Therefore, during infection mediated by SARS-CoV-2, the CD147 functions by interaction by cyclophilin A (CyPA) (Liu et al., 2020) . Even though, the binding affinity of the viral S protein to CD147 is 12 folds than that of ACE2 (Kini and Kundu, 2020), yet the CD147 surface density on host cells permits the formation of various bonds with necessary combined affinity (Kini and Kundu, 2020) . The interaction between S protein and CD147 was confirmed by surface plasmon resonance, using Biacore analysis (Hui et al., 2020) . The HEK293 expressing CD147 has been reported to attach to the SARS-CoV-2, with high affinity, thereby indicating the significance of CD147 in the host J o u r n a l P r e -p r o o f Journal Pre-proof organism (Chen et al., 2005) . On account of the relationship between the COVID-19 infection and metabolic disorders, as well as the interaction between CD147 and virus entry, CoV-2 in the host cell (Saltos and Saltos, 2020) . Also, a direct interaction has been reported between RBD region of S1 subunit of SARS-CoV-2 and CD147, as per coimmunoprecipitation assay and surface plasmon resonance (Rodrigues-Diez et al., 2020) . Furthermore, a study reported the participation of CD147-cyclophilin A axis in pathogenesis of kidney injury in COVID-19 patients (Su et al., 2021) . IL-6 has been reported to facilitate CD147 expression, which is the key receptor for SARS-CoV-2 entry (Hu et al., 2016; Arendt et al., 2012; Dai et al., 2012) . In the host, this might be a normal adaptive process, as its level, in combination with cyclophilins, aids in immune cell recruitment to inflammation sites, via chemokine-like activity (Yurchenko et al., 2006) . CD147 may abet IL-6, with intravascular presence of plasminogen activator inhibitor-1, Von Willebrand factor and vitronectin, which creates the prothrombotic phenotype in multiple cases of SARS (Wu e al., 2006; Jin et al., 2017) . However, a study indicated the absence of evidence, supporting the role of CD147 as a direct SARS-CoV-2 spine binding receptor (Shilts et al., 2021) . Very weak interactions were reported between the recombinant forms of SARS-CoV-2 spike and CD147 on human cell surfaces, which was confirmed by using specialized assays. Therefore, this supported their finding that no direct interaction of viral spike protein was found with any of the two CD147 isoforms. Also, no change was observed in the susceptibility towards SARS-CoV-2 infection, when CD147 was removed from the ). Endocytosis is reported to be significantly regulated by Rab5, which is located at early endosome (Saitoh et al., 2017) . The study detected co-localization of spike CD147 and Rab5 in BHK-21-CD147 cells and lung tissues, isolated from COVID-19 infected patients, which indicated that virions and CD147 exhibited endocytosis, thereby supporting the entry of SARS-CoV-2 into the host cell, via CD147-mediated endocytosis . This, therefore, strengthens the involvement of CD147 in SARS-CoV-2 entry, and take the researchers a step further towards this entry route. A model has been explained to portray the dual role of the receptors, facilitating viral entry and infection in the respiratory and circulatory systems, by distributing both CD147 and ACE2 on the respective tissues, where both these receptors are found in the endothelial lining of vasculature and lungs (Hamming et al., 2004; Bian et al., 2020; Yurchenko et al., 2006; Muramatsu, 2016) . However, not ACE2, but only CD147 is found in the white and red blood cells Aguiar et al., 2020) . The expression shows that these two might be two complimentary receptors in promoting the viral infection. In order to study the infection ability of SARS-CoV-2, hCD147 mice were constructed, where the lungs of these mice, infected with virus, were found to be loaded with virus particles, which was not the case of infected wild-type mice, after 48 hours of infection. The mice stained with eosin and haematoxylin were found to develop pneumonia, along with serofluid exudation, thickening of the alveolar septum, formation of hyaloid membrane, infiltration of inflammatory cells and pulmonary consolidation, without any histopathological alterations. However, the wild-type mice did not experience any histopathological alterations. These results indicated that the SARS-CoV-2-susceptible mouse model is successfully developed and established the significant involvement of CD147, as a receptor for the infection, mediated by the SARS-CoV-2. This functions as an alternative virus receptor for ACE2-defiant cells . Despite the contradictory outcomes in studies, the previous data aims to provide a substantial evidence and platform to evaluate the role of CD147 in COVID-19 disease, which might unfold the mysteries of the COVID-19 disease. 5.6.Superiority of CD147 over ACE2 in COVID-19 CD147 can explain two things, which ACE2 receptor alone cannot, where the first one being risk of elevated levels of blood glucose in prognosis of COVID-19, and the second one being susceptibility of T-cells towards COVID-19. Individuals with type-2 diabetes, with poor blood glucose regulation, exhibited greater mortality rate, as compared to those individuals where the blood glucose level was well maintained (Yong, 2020) . This was explained by the fact that the increase in the blood glucose level elevated the expression of CD147 receptor on the immune cells. which has been reported to be caused by CD147 pathway, and not ACE2, because the expression levels of hACE2 is very low in T cells, unlike CD147 (Yong, 2020) . A study investigated the expression levels of CD147 and ACE2 receptors, as well as serine protease TMPRSS2 in mouse brain and human cell lines, using western blot and qRT-PCR. As per the results their concentration levels in different tissues varied from that of lungs (Qiao et al., 2020) . The mouse brain cell lines and tissues expressed lower ACE2 and greater CD147 levels, unlike the lung tissue and cell line, whereas TMPRSS2 exhibited a consistent expression both in brain cell lines and mouse lung tissues (Qiao et al., 2020) . The central nervous system (CNS) is more like to be infected with the COVID-19 disease, via CD147 receptors and TMPRSS2 protease, and not ACE2 receptors (Qiao et al., 2020) . Owing to the availability of both CD147 and TMPRSS2, neuron and microglia exhibited the possibility of SARS-CoV-2 infection, however, astrocyte is less likely to be infected (Qiao et al., 2020) . Greater expression of TMPRSS2 and CD147 were found in cortex, cerebellum and hypophysis of mouse brain. Also, it has been revealed that S protein of SARS-CoV-2 has lower affinity towards CD147, as compared to ACE2, which explains the reason behind lower viral infection in the brain (Qiao et al., 2020) . As per the recent investigations, CD147 has been identified as the receptor for SARS-CoV-2 infection in the endothelial cells (Saltos and Saltos, 2020) , and its -Shala et al., 2020) . Furthermore, CD147 is elevated in other disorders, including the ones which are associated with the COVID-19 infection, such as diabetes, pulmonary hypertension, obesity and renal disease (Ahmetaj-Shala et al., 2020) . Also, CD147 induces extracellular matrix metalloproteinases (MMPs), which may be significant while considering the role vasculature, primarily endothelial dysfunction, in promoting pulmonary fibrosis, one of the most detrimental COVID-19 complications (Ahmetaj-Shala et al., 2020) . A detailed understanding of the interaction between CD147 and SARS-CoV-2 will provide a comprehensive insight and identify suitable therapeutic targets for COVID-19 treatment (Ahmetaj-Shala et al., 2020) . Owing to the role of CD147, it has been identified as a suitable target in the treatment of inflammatory disorders (Zhu et al., 2014 (Ramos et al., 2021) . Furthermore, J o u r n a l P r e -p r o o f Journal Pre-proof changes in the CD147-cyclophilin A signalling process and impairment of calcium homeostasis have promoted inflammatory injury and thrombosis in heart failure and lungs (Loh, 2020) . Thus, CD147 can be used as a suitable therapeutic target to retard inflammation and progression of the disease (Ramos et al., 2021) . The free binding energy of estradiol benzoate and CD147 is the most favourable, as indicated by the outcomes of MD simulation (Sheim, 2020) . Estradiol benzoate is the estradiol (naturally occurring hormone) prodrug, which functions as a major sex hormone in women . Studies have indicated that the COVID-19 incidence is more in men as compared to women, the reason considered to be elevated estradiol levels in women (Molina et al., Magagnoli et al., 2020) . The animal studies have suggested blockage of inflammatory events by estrogen, which has resulted in improvement in COVID-19 patients (Rosenberg et al., 2020) . Furthermore, irinotecan and olaparib also possess a suitable free binding energy with CD147 (Sheim, 2020). Despite the optimised results, parenteral administration, non-availability in market as well as improper knowledge and data limits its use as therapeutic candidate for COVID-19 treatment . A tetracycline analogue, doxycycline, ameliorates the levels of CD147 in gallbladder cell line (Wang et al., 2017; Emingil et al., 2008) . Moreover, azithromycin can be considered as a possible candidate for mitigating the effects of SARS-C0V-2, owing to its role in interfering with CD147 receptor, and preventing the invasion of malaria-causing Plasmodium falciparum beta adrenergic blockers; ivermectin, which promotes non-availability of CD147 towards SARS-CoV-2; CD147-downregulating statins; Melatonin, hindering the CD147-mediated signalling pathway; doxycycline; Azithromycin etc., thereby providing a critical opportunity for the global researchers and virologists to observe the viral entry process from a different perspective, simultaneously obtaining answers to many other questions. A study, however, reveals the lack of evidence supporting the role of CD147 receptor in SARS-CoV-2 entry and identifies weak spike-receptor interactions, yet does not rule out the possibility of the possible significant involvement of the receptor as an alternative viral entry mechanism. There is a stringent need of development of more investigations and studies, to evaluate clearly the spike-receptor relationship, which, the authors believe, would definitely provide reliable evidence in favour of the relationship, to confirm the potential role of CD147 in COVID -19 infection and associated comorbidities. The manuscript aims to provide a comprehensive approach towards the involvement of CD147 in COVID-19 disease, aiming to combat with the prevailing infection and put an end to it. Despite the already established entry mechanism, via ACE-2, the CD147 mediated entry provides a valid explanation regarding the prevalence of infection in individuals with other comorbidities, and identifies the link between them. The ultimate goal of finding a cure cannot be achieved without in-depth analysis of the problem and identification of suitable connections, that might create a reliable pathway, leading towards an appropriate therapeutic regimen. These findings would possibly aid the researchers in the development of a suitable therapy, however, still many investigations are Interleukin-6 drives multiple myeloma progression by up-regulating of CD147/emmprin expression Clinical features of patients infected with 2019 novel coronavirus in The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health -The latest 2019 novel coronavirus outbreak in Wuhan, China Coronavirus spike protein and tropism changes Coronavirus spike protein and tropism changes Coronavirus spike protein and tropism changes Inhibition of CD147 (cluster of differentiation 147) ameliorates acute ischemic stroke in mice by reducing thromboinflammation EMMPRIN (CD147) regulation of MMP-9 in bronchial epithelial cells in COPD Viral dynamics in mild and severe cases of COVID-19 The potential of melatonin in the prevention and attenuation of oxidative hemolysis and myocardial injury from cd147 SARS-CoV-2 spike protein receptor binding Basolateral CD147 induces hepatocyte polarity loss by E-cadherin ubiquitination and degradation in hepatocellular carcinoma progress Melatonin is responsible for rice resistance to rice stripe virus infection through a nitric oxide dependent pathway Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Erythrocyte Aggregation as a Determinant of Blood Flow: Effect of pH, Temperature and Osmotic Pressure Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv ACE2, CD147) through virtual screening and molecular dynamic simulations COVID 19 cytokine storm: the anger of inflammation Microtubuledependent endosomal sorting of clathrin-independent cargo by Hook1 How sewage could reveal true scale of coronavirus outbreak Significant biochemical, biophysical and metabolic diversity in circulating human cord blood reticulocytes Anemias: Red blood cell morphology and approach to diagnosis Knock out of the BASIGIN/CD147 chaperone of lactate/H+ symporters dis proves its pro-tumour action via extracellular matrix metallo proteases (MMPs) induction Matrix metalloproteinase-9 expression in asthma Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses The expression of SARS-CoV-2 receptor ACE2 and CD147, and protease TMPRSS2 in human and mouse brain cells and mouse brain tissues Distribution of ACE2, CD147, cyclophilins, CD26 and other SARS-CoV-2 associated molecules in human tissues and immune cells in health and disease Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors Biomedical Waste amid COVID-19: Perspectives from Bangladesh The Coronavirus Disease 2019 (COVID-19): Key Emphasis on Melatonin Safety and Therapeutic Efficacy Retinal outcomes of COVID-19: Possible role of CD147 and cytokine storm in infected patients with diabetes mellitus. Diabetes Research and Clinical Practice Statins: Could an old friend help in the fight against COVID-19? Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in Characterization of a novel coronavirus associated with severe acute respiratory syndrome Environmental effects of COVID-19 pandemic and potential strategies of sustainability Immune-epidemiological parameters of the novel coronavirus-a perspective Rab5-regulated endocytosis plays a crucial role in apical extrusion of transformed cells Entry of SARS-CoV2 through the basal surface of alveolar endothelial cells-a proposed mechanism mediated by CD147 in COVID-19 Available at Efcacy of melatonin on serum pro-infammatory cytokines and oxidative stress markers in relapsing remitting multiple sclero sis Downregulation of monocytic differentiation via modulation of CD147 by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors Efects of circa dian rhythm hormones melatonin and 5-methoxytryptophol on COXs, Raf-1 and STAT3 Ivermectin for COVID-19 Treatment: Clinical Response at Quasi-Threshold Doses Via Hypothesized Alleviation of CD147-Mediated Vascular Occlusion Ivermectina for COVID 19 treatment Clinical response at quasi-threshold doses via hypothesized alleviation of CD147 mediated vascular occlusive Extracellular matrix metalloproteinase inducer (CD147) is a novel receptor on platelets, activates platelets, and augments nuclear factor kappaB-dependent inflammation in monocytes Role of melatonin in the treatment of COVID -19 as an adjuvant through cluster differentiation 147 (CD147) The role of melatonin in diabetes: therapeutic implications No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor Can melatonin reduce the severity of COVID-19 pandemic? Environmentally sustainable management of used personal protective equipment Inhibition of functional hyaluronan-CD44 interactions in CD133-positive primary human ovarian carcinoma cells by small hyaluronan oligosaccharides Mechanisms of endocytosis utilized by viruses during infection Indirect implications of COVID-19 towards sustainable environment: an investigation in Indian context The role of melatonin in the onset and progression of type 3 diabetes Red blood cell age determines the impact of storage and leukocyte burden on cell adhesion molecules, glycophorin A and the release of annexin V Use of aspirin in reduction of mortality of COVID-19 patients: A meta-analysis Melatonin attenuates angiotensin II-induced cardiomyocyte hypertrophy through the CyPA/CD147 signaling pathway Expression of CD147 and Cyclophilin A in Kidneys of Patients with COVID-19 Red blood cell surface adhesion molecules: Their possible roles in normal human physiology and disease The Human Protein Atlas (2020) BSG protein expression-Summary The CD147-Hyaluronan Axis in Cancer Self-assembly of severe acute respiratory syndrome coronavirus membrane protein CD147 as a target for COVID-19 treatment: suggested efects of azithromycin and stem cell engagement CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement Beta-Adrenergic Blockers as a Potential Treatment for COVID-19 Extracellular Matrix Metalloproteinase Inducer EMMPRIN (CD147) in Cardiovascular Disease Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS Expression of CD147 (EMMPRIN) on neutrophils in rheumatoid arthritis enhances chemotaxis, matrix metalloproteinase production and invasive ness of synoviocytes Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells SARS-CoV-2 invades host cells via a novel route: CD147-spike protein SARS-CoV-2 invades host cells via a novel route: CD147-spike protein SARS-CoV-2 invades host cells via a novel route: CD147-spike protein Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4 Effects of matrix metalloproteinase inhibitor doxycycline and CD147 antagonist peptide-9 on gallbladder carcinoma cell lines CD147/EMMPRIN acts as a functional entry receptor for measles virus on epithelial cells Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (nCoV) Infection Is Suspected: Interim Guidance. WHO website Macrolides rapidly inhibit red blood cell invasion by the human malaria parasite, Plasmodium falciparum SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China Analysis of thrombotic factors in severe acute respiratory syndrome (SARS) patients The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature Overlooked Receptors in Covid-19: What ACE2 Alone Cannot Explain CD147 increases mucus secretion induced by cigarette smoke in COPD Dealing with the family: CD147 interactions with cyclophilins CD147 is a signaling receptor for cyclophilin B The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article Indirect effects of COVID-19 on the environment Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target Disrupting CD147-RAP2 interaction abrogates erythrocyte invasion by Plasmodium falciparum COVID-19: melatonin as a potential adjuvant treatment HAb18G/CD147 promotes cell motility by regulating annexin IIactivated RhoA and Rac1 signaling pathways in hepatocellular carcinoma cells Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study CD147: a novel modulator of inflammatory and immune disorders